Development of a Patient Decision Aid for Atopic Dermatitis Systemic Treatments in Adults

Systemic Lupus Erythematosus

Implementation outcomes of a patient decision-aid in a diverse population with systemic lupus erythematosus in 15 U.S. rheumatology clinics

Rheumatology (Oxford)

Singh JA, Hearld LR, Eisen S, Chatham WW, Narain S, Annapureddy N, Kamen DL, Trotter K, Majithia V, Lee Ching C, Aouhab Z, Venuturupalli S, Wallace DJ, Ramsey-Goldman R, Kim A, McMahon M, Sam Lim S, Bhairavarasu K, Meara A, Kalunian K, Beasley M, Implementing DEcision-Aid for Lupus in clinics (IDEAL) Consortium

doi: 10.1093/rheumatology/keaf205

Atopic Dermatitis

Efficacy and safety of lebrikizumab in adult and adolescent patients with moderate-to-severe atopic dermatitis inadequately controlled with or ineligible for ciclosporin A: a placebo-controlled, randomized phase IIIb clinical study (ADvantage)

Br J Dermatol

Warren RB, de Bruin-Weller M, Tsianakas A, Khemis A, Szepietowski JC, Hong HC, Mihaylov Y, Falqués M, Agell H, Massana E, Gil EG, Coll R, Weidinger S

doi: 10.1093/bjd/ljaf285

Systemic Lupus Erythematosus

Factors associated with delay in the diagnosis and treatment of systemic lupus erythematosus in adult patients: a systematic review

Rheumatology (Oxford)

Ramírez-Flores MF, Hernandez-Garduno A, Quintana R, Fuentes-Silva Y, Nieto R, Cano-Gámez T, Ferreyra L, Ceballos MF, Gastelum-Strozzi A, Pons-Estel BA, Pons-Estel G, Peláez-Ballestas I

doi: 10.1093/rheumatology/keaf384

Atopic DermatitisPsoriasis

The 487-gene expression profile test guides systemic therapy selection to improve outcomes for patients with atopic dermatitis: Results from a prospective trial

J Am Acad Dermatol

Silverberg JI, Eichenfield LF, Armstrong AW, Bagel J, Lockshin B, Boh E, Koo J, Farberg AS, Goldberg MS, Quick AP, Lebwohl MG

doi: 10.1016/j.jaad.2026.02.034

Atopic Dermatitis

Risk of Developing Pediatric Uveitis Among Patients With Early-Onset Atopic Dermatitis

JAMA Ophthalmol

Chu YY, Sung CH, Lin YS, Ho CH, Chen YC, Lee WA, Kuo SC

doi: 10.1001/jamaophthalmol.2025.0366

Atopic Dermatitis

Efficacy and Safety of Upadacitinib Dose Escalation and Reduction in Adult Patients With Moderate-To-Severe Atopic Dermatitis: Results of a Randomized, Blinded, Treat-To-Target, Multicenter Phase 3b/4 Study (Flex Up)

Br J Dermatol

Gooderham M, Torres T, Imafuku S, Rademaker M, Prajapati VH, Tsianakas A, Murrell DF, Owczarek W, Han Y, Lee WJ, Levy G, Ibrahim N, Moreira A, Shams K

doi: 10.1093/bjd/ljaf236

Atopic Dermatitis

Skin Clearance, Duration of Treatment-free Interval, and Safety of Tapinarof Cream 1% Once Daily: Results from ADORING 3, a 48-week Phase 3 Open-label Extension Trial in Adults and Children Down to 2 Years of Age with Atopic Dermatitis

J Am Acad Dermatol

Bissonnette R, Gold LS, Kircik L, Simpson EL, Eichenfield LF, Browning J, Hebert AA, Alexis AF, Soong W, Piscitelli SC, Tallman AM, Rubenstein DS, Brown PM, Silverberg JI

doi: 10.1016/j.jaad.2025.05.1391

Rheumatoid Arthritis

Standardizing health outcomes for people with rheumatoid arthritis receiving disease modifying drug therapy: A rapid review of patient-decision aids and preference studies to inform the development of OMERACT Health Outcome Descriptors

Semin Arthritis Rheum

Raskin N, Hiligsmann M, Rebutoc AR, Bansback N, Boonen A, Buchbinder R, Falahee M, Fraenkel L, Marshall DA, Maxwell L, Nieuwlaat R, Proulx L, Saadat P, Shea B, Tugwell P, Wiercioch W, Beaton D, Richards P, Schünemann H, Guillemin F, Hazlewood GS

doi: 10.1016/j.semarthrit.2025.152769

Autoimmune Disease

The development of a risk threshold to aid risk stratified approach to monitoring for haematological, hepatic and/or renal adverse drug reactions during established conventional synthetic DMARD treatment for systemic autoimmune rheumatic diseases: a RAND/UCLA Appropriateness Method consensus study

Rheumatology (Oxford)

Ablewhite J, Nakafero G, Almayahi A, Bechman K, Ahmed A, Davidson A, De Vere H, Dhillon E, Foulkes A, Gullick N, Heaton R, Hider S, Kyle S, Nowak K, Rose-Parfitt E, Ryan S, Tan SY, Wood N, Zebate G, Parsons K, Holmes J, Twohigg H, Reynolds JA, Mercer L, Galloway J, Abhishek A

doi: 10.1093/rheumatology/keag031

Related content

Implementation outcomes of a patient decision-aid in a diverse population with systemic lupus erythematosus in 15 U.S. rheumatology clinics

Efficacy and safety of lebrikizumab in adult and adolescent patients with moderate-to-severe atopic dermatitis inadequately controlled with or ineligible for ciclosporin A: a placebo-controlled, randomized phase IIIb clinical study (ADvantage)

Factors associated with delay in the diagnosis and treatment of systemic lupus erythematosus in adult patients: a systematic review

The 487-gene expression profile test guides systemic therapy selection to improve outcomes for patients with atopic dermatitis: Results from a prospective trial

Risk of Developing Pediatric Uveitis Among Patients With Early-Onset Atopic Dermatitis

Efficacy and Safety of Upadacitinib Dose Escalation and Reduction in Adult Patients With Moderate-To-Severe Atopic Dermatitis: Results of a Randomized, Blinded, Treat-To-Target, Multicenter Phase 3b/4 Study (Flex Up)

Skin Clearance, Duration of Treatment-free Interval, and Safety of Tapinarof Cream 1% Once Daily: Results from ADORING 3, a 48-week Phase 3 Open-label Extension Trial in Adults and Children Down to 2 Years of Age with Atopic Dermatitis

Standardizing health outcomes for people with rheumatoid arthritis receiving disease modifying drug therapy: A rapid review of patient-decision aids and preference studies to inform the development of OMERACT Health Outcome Descriptors

The development of a risk threshold to aid risk stratified approach to monitoring for haematological, hepatic and/or renal adverse drug reactions during established conventional synthetic DMARD treatment for systemic autoimmune rheumatic diseases: a RAND/UCLA Appropriateness Method consensus study